The ubiquitin-like protein FAT10 stabilizes eEF1A1 expression to promote tumor proliferation in a complex manner

Cancer Research

Volumn 76, Issue 16, 2016, Pages 4897-4907

  Liu, Xiuxia ^a,b   Chen, Leifeng ^a,b,c   Ge, Jin ^a,b,c   Yan, Chen ^a,c   Huang, Zixi ^a,b   Hu, Junwen ^a   Wen, Chongyu ^a,b,c   Li, Ming ^a,b,c   Huang, Da ^a,b,c   Qiu, Yumin ^a,b,c   Hao, Haibin ^a,b,c   Yuan, Rongfa ^a,c   Lei, Jun ^a,c   Yu, Xin ^a,c   Shao, Jianghua ^a,b,c  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Province Key Laboratory of Molecular Medicine   (China)

^c Jiangxi Province Engineering Research Center of Hepatobiliary Disease   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTIC TRANSLATION ELONGATION FACTOR 1A1; FAT10 PROTEIN; LYSINE; PROTEASOME; PROTEIN; UBIQUITIN; UBIQUITIN LIKE PROTEIN; UNCLASSIFIED DRUG; EEF1A1 PROTEIN, HUMAN; ELONGATION FACTOR 1; UBD PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UBIQUITINATION; ANIMAL; CONFOCAL MICROSCOPY; EXPERIMENTAL NEOPLASM; IMMUNOPRECIPITATION; METABOLISM; NUDE MOUSE; PATHOLOGY; POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; HETEROGRAFTS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS, EXPERIMENTAL; PEPTIDE ELONGATION FACTOR 1; POLYMERASE CHAIN REACTION; UBIQUITIN; UBIQUITINATION; UBIQUITINS;

EID: 84982083129     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3118     Document Type: Article

References (44)

1. Aichem A, Groettrup M. Detection and analysis of FAT10 modification. Methods Mol Biol 2012;832:125-32.
2. Buchsbaum S, Bercovich B, Ciechanover A. FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination. Mol Biol Cell 2012;23:225-32.
3. Zhang DW, Jeang KT, Lee CG. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006;25:2318-27.
4. Lim CB, Zhang D, Lee CG. FAT10, a gene up-regulated in variouscancers, is cell-cycle regulated. Cell Div 2006;1:20.
5. Lee CG, Ren J, Cheong IS, Ban KH, Ooi LL, Yong TS, et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003;22:2592-603.
6. Raasi S, Schmidtke G, Groettrup M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J Biol Chem 2001;276:35334-43.
7. Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, et al. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3beta pathway. Oncogene 2014;33:909-20.
8. Theng SS, Wang W, Mah WC, Chan C, Zhuo J, Gao Y, et al. Disruption of FAT10-MAD2 binding inhibits tumor progression. Proc Natl Acad Sci U S A 2014;111:E5282-91.
9. Aichem A, Pelzer C, Lukasiak S, Kalveram B, Sheppard PW, Rani N, et al. USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun 2010;1:69-81.
10. Leng L, Xu C, Wei C, Zhang J, Liu B, Ma J, et al. A proteomics strategy for the identification of FAT10-modified sites by mass spectrometry. J Proteome Res 2014;13:268-76.
11. Aichem A, Kalveram B, Spinnenhirn V, Kluge K, Catone N, Johansen T, et al. The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci 2012;125:4576-85.
12. Yuan R, Wang K, Hu J, Yan C, Li M, Yu X, et al. Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying beta-catenin degradation. Cancer Res 2014;74:5287-300.
13. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. FAT10, a ubiquitin-independent signal for proteasomal degradation. Molecular and Cellular Biology 2005;25:3483-91.
14. Kapp LD, Lorsch JR. The molecular mechanics of eukaryotic translation. Annu Rev Biochem 2004;73:657-704.
15. Schulz I, Engel C, Niestroj AJ, Kehlen A, Rahfeld JU, Kleinschmidt M, et al. A non-canonical function of eukaryotic elongation factor 1A1: regulation of interleukin-6 expression. Biochim Biophys Acta 2014;1843:965-75.
16. Scaggiante B, Dapas B, Bonin S, Grassi M, Zennaro C, Farra R, et al. Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression. Br J Cancer 2012;106:166-73.
17. Leclercq TM, Moretti P, Pitson SM. Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 2011;30:372-8.
18. Zhu G, Yan W, He HC, Bi XC, Han ZD, Dai QS, et al. Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1a expression. Mol Med 2009;15:363-70.
19. Scaggiante B, Dapas B, Grassi G, Manzini G. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J 2006;273:1350-61.
20. Yu X, Liu X, Liu T, Hong K, Lei J, Yuan R, et al. Identification of a novel binding protein of FAT10: eukaryotic translation elongation factor 1A1. Dig Dis Sci 2012;57:2347-54.
21. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281-308.
22. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346:1258096.
23. Schmidtke G, Aichem A, Groettrup M. FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta 2014;1843:97-102.
24. Yue JP, Shukla R, Accardi R, Zanella-Cleon I, Siouda M, Cros MP, et al. Cutaneous human papillomavirus type 38 E7 regulates actin cytoskeleton structure for increasing cell proliferation through CK2 and the eukaryotic elongation factor 1A. J Virol 2011;85:8477-94.
25. Yan G, You B, Chen SP, Liao JK, Sun J. Tumor necrosis factor-a downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-a1. Circ Res 2008;103:591-7.
26. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, et al. C-Raf antagonizes apoptosis induced by IFN-a in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 2007;14:952-62.
27. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkBa inhibits NF-kB activation. Mol Cell 1998;2:233-9.
28. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002;419:135-41.
29. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, et al. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 2006;8:1424-31.
30. Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 2007;100:1276-91.
31. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006;66:921-8.
32. Rani N, Aichem A, Schmidtke G, Kreft SG, Groettrup M. FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasomemediated proteolysis. Nat Commun 2012;3:132-6.
33. Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, et al. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Sci Transl Med 2015;7:143r-304r.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
35. Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, Wu WZ, et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683-91.
36. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015;517:209-13.
37. Yuan Y, Wang J, Li J, Wang L, Li M, Yang Z, et al. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res 2006;12:6687-95.
38. Koiwai K, Maezawa S, Hayano T, Iitsuka M, Koiwai O. BPOZ-2 directly binds to eEF1A1 to promote eEF1A1 ubiquitylation and degradation and prevent translation. Genes Cells 2008;13:593-607.
39. Austin KJ, Carr AL, Pru JK, Hearne CE, George EL, Belden EL, et al. Localization of ISG15 and conjugated proteins in bovine endometrium using immunohistochemistry and electron microscopy. Endocrinology 2004;145:967-75.
40. Vertegaal AC. Uncovering ubiquitin and ubiquitin-like signaling networks. Chem Rev 2011;111:7923-40.
41. Papouli E, Chen S, Davies AA, Huttner D, Krejci L, Sung P, et al. Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol Cell 2005;19:123-33.
42. Bogachek MV, De Andrade JP, Weigel RJ. Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors. Cancer Res 2015;75:11-5.
43. Bialas J, Groettrup M, Aichem A. Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation. PLoS One 2015;10:e120329.
44. Hipp MS, Raasi S, Groettrup M, Schmidtke G. NEDD8 ultimate Buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem 2004;279:16503-10.